Advances in clinical development for vaccines and therapeutics against respiratory virus infections
J.L. van der Plas

Citation
Advances in clinical development for vaccines and therapeutics against respiratory virus infections. (2023, September 26). Advances in clinical development for vaccines and therapeutics against respiratory virus infections. Retrieved from https://hdl.handle.net/1887/3642223

Version: Publisher's Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/3642223

Note: To cite this publication please use the final published version (if applicable).
ADVANCES IN CLINICAL DEVELOPMENT FOR VACCINES AND THERAPEUTICS AGAINST RESPIRATORY VIRUS INFECTIONS
# Chapter 1: Introduction

## Section 1: Respiratory Syncytial Virus

### Chapter 2: Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season

### Chapter 3: First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial

## Section 2: Influenza Virus

### Chapter 4: Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (Gem) particles (FluGEM®): a randomized, double-blind, controlled, ascending dose study in healthy adults and elderly

## Section 3: SARS-CoV-2 and Clinical Development during Pandemics

### Chapter 5: Viral clearance, pharmacokinetics and tolerability of ensolvibep in patients with mild to moderate COVID-19 – a phase 2a, open-label, single dose escalation study

### Chapter 6: Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study

### Chapter 7: Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation

### Chapter 8: How to expedite early-phase SARS-CoV-2 vaccine trials in pandemic setting - A practical perspective

### Chapter 9: Discussion and future perspectives

---

**Promotor**
Prof. dr. J. Burggraaf

**Co-promotor**
Dr. I.M.C. de Visser-Kamerling

**Leden promotiecommissie**
Prof. dr. L.G. Visser
Prof. dr. W.J.M. Spaan
Prof. dr. B.C.P. Koch (Erasmus Medisch Centrum, Rotterdam)
Prof. dr. M. van Egmond (Amsterdam Universitair Medisch Centrum, Amsterdam)